Stock Taper
MOLN
MOLECULAR PARTNERS AG
NASDAQ
$4.50
▼ DOWN 3.28% (-0.15)

KEY STATISTICS

Market Cap$168.80 M
52w High$5.36
52w Low$3.53
Dividend Yield
Frequency
P/E-2.64
Volume1.53K
Shares Out.37.51M

COMPANY

LEADERSHIP

Patrick Amstutz
CHIEF EXECUTIVE
Patrick Amstutz

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
134

PRICE TARGET

Target High$29.00
Target Low$13.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.
OCT
29
THU

PRICE

$4.50 ▼ DOWN 3.28% (−$0.15)
$4.50$4.60$4.70$4.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.50

About Molecular Partners AG

https://www.molecularpartners.com ↗

Molecular Partners AG is a Swiss clinical-stage biopharmaceutical company developing DARPin-based therapeutics for ophthalmology, oncology, and infectious diseases, with collaborations including Novartis, Amgen, and AbbVie.

INDUSTRY

Biotechnology

A PRODUCT MOLECULAR PARTNERS AG IS KNOWN FOR

MP0533
MP0533

An investigational multi-specific DARPin therapy targeting three tumor antigens, currently in Phase 1 trials for AML and MDS, is Molecular Partners' most advanced candidate, aiming to activate the immune system against cancer cells.

Revenue by Geography

MapREGIONFY2021FY2022FY2023FY2024
SWITZERLAND$179.9M $7.04M $4.97M
UNITED STATES$9.33M $9.65M $0

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
NEUTRAL 1
2 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
ALEC$2.34COMPARE
PEPG$3.08COMPARE
CRBP$10.91COMPARE
NKTX$2.76COMPARE
MIST$1.16COMPARE
CRDF$0.94COMPARE
RANI$0.84COMPARE
ELTX$2.84COMPARE